Transformational Research: Canada 2020 (Alzheimer’s & Related)

Goal: To provide funding for translational research that will accelerate the development of therapeutics for neurodegenerative diseases of aging.

Funding: A maximum of $1,500,000 over up to 3 years per project. Encouraging applications at all funding levels from $300,000 to $1,500,000, without need for preliminary data.

Applicant Eligibility: Eligible Principal Applicants must be researchers working in Canada at least 30% of the time at or above the level of Assistant Professor or equivalent, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Co-Applicants/Collaborators must be at the post-doctoral level or above and can be working outside Canada.

Applicants may appear in any role on any number of projects.

Project Eligibility: Projects must meet the following conditions to be eligible:

• Be translational research (excluding clinical trials and clinical trial sub-studies) that accelerates the development of therapeutics for neurodegenerative diseases of aging.
  • Clinical trials and clinical trial sub-studies should be submitted to the Early-Phase Clinical Trials or Rapid Response programs; however other translational research using humans or human samples/data is in scope.
• Be the development of a therapeutic and/or tool and/or select complementary approaches (Please refer to the Program Details for more information on complementary approaches that are in scope)